MA28146A1 - Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique - Google Patents

Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique

Info

Publication number
MA28146A1
MA28146A1 MA28995A MA28995A MA28146A1 MA 28146 A1 MA28146 A1 MA 28146A1 MA 28995 A MA28995 A MA 28995A MA 28995 A MA28995 A MA 28995A MA 28146 A1 MA28146 A1 MA 28146A1
Authority
MA
Morocco
Prior art keywords
induced
methods
exercise
preventing
jtv
Prior art date
Application number
MA28995A
Other languages
English (en)
Inventor
Andrew Robert Marks
Donald W Landry
Shi Xian Deng
Zhen Zhuang Cheng
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MA28146A1 publication Critical patent/MA28146A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Cette invention concerne un procédé visant à limiter ou à prévenir une baisse du niveau de protéines FKBP12.6 liées à RyR2 chez un sujet, une méthode de traitement ou de prévention de l'arythmie cardiaque induite par l'exercice physique chez un sujet, ainsi qu'une méthode de prévention de la mort cardiaque subite induite par l'exercice physique chez un sujet. Cette invention concerne également les utilisations de JTV-519 dans ces méthodes. Cette invention concerne en outre des méthodes permettant d'identifier des agents utilisés pour prévenir la mort cardiaque subite induite par l'exercice physique, ainsi que les agents identifiés par ces méthodes. Cette invention concerne par ailleurs des méthodes de prévention de la mort cardiaque subite induite par l'exercice physique consistant à administrer ces agents. En outre, cette invention concerne des méthodes permettant de synthétiser le JTV-519, le JTV-519 radio marqué et des intermédiaires et dérivés de la 1,4-benzothiazépine.
MA28995A 2003-10-07 2006-05-02 Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique MA28146A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/680,988 US20040229781A1 (en) 2000-05-10 2003-10-07 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias

Publications (1)

Publication Number Publication Date
MA28146A1 true MA28146A1 (fr) 2006-09-01

Family

ID=34465444

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28995A MA28146A1 (fr) 2003-10-07 2006-05-02 Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique

Country Status (14)

Country Link
US (1) US20040229781A1 (fr)
EP (1) EP1684735A4 (fr)
JP (1) JP2007507536A (fr)
KR (1) KR20060110290A (fr)
CN (1) CN100502845C (fr)
AU (1) AU2004281672A1 (fr)
BR (1) BRPI0415434A (fr)
CA (1) CA2541847A1 (fr)
EA (1) EA011357B1 (fr)
MA (1) MA28146A1 (fr)
NO (1) NO20062063L (fr)
SG (1) SG147414A1 (fr)
WO (1) WO2005037195A2 (fr)
ZA (1) ZA200603593B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1784150A4 (fr) * 2004-09-01 2011-05-11 Nexmed Holdings Inc Systeme d'administration transdermique d'une composition antiemetique
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008140592A2 (fr) * 2006-11-29 2008-11-20 Armgo Pharma, Inc. 1,4-benzothiazépines radioactivement marquées et procédés de criblage de composés qui lient les récepteurs de la ryanodine
KR101260859B1 (ko) * 2008-03-03 2013-05-06 르 라보레또레 쎄르비에르 감마-아미노알킬벤젠으로부터 벤조티아제핀을 제조하는 방법
WO2010120382A1 (fr) * 2009-04-15 2010-10-21 State Of Oregon By And Through The State Board Of Higher Education On Behalf Of Portland State University Composés et procédés de modulation de l'activité des canaux de libération de calcium
EP2708535A1 (fr) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
WO2023091524A1 (fr) * 2021-11-16 2023-05-25 Armgo Pharma, Inc. Composés thérapeutiques

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) * 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
DE3561317D1 (en) * 1984-01-27 1988-02-11 Ajinomoto Kk Manufacture of heptanoic acid derivatives
US4841055A (en) * 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
US4723012A (en) * 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5124056A (en) * 1987-07-24 1992-06-23 Exxon Chemical Patents Inc. Polymer substituted amido-amine Mannich Base lubricant dispersant additives
JPS6445706A (en) * 1987-08-17 1989-02-20 Sumitomo Electric Industries Production of composite carbon nitride
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
EP0446374B1 (fr) * 1989-09-30 1996-02-07 Kirin Beer Kabushiki Kaisha Procede de production de plants
KR940000166B1 (ko) * 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
CA2056453A1 (fr) * 1990-03-30 1991-10-01 Koji Kobayashi Derive de la 4h-3,1-benzoxazin-4-one
US5517652A (en) * 1990-05-30 1996-05-14 Hitachi, Ltd. Multi-media server for treating multi-media information and communication system empolying the multi-media server
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
EP0638560A4 (fr) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical Medicament utilise pour traiter l'osteoporose et compose de diazepine.
AU3143593A (en) * 1991-12-20 1993-07-28 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin E2 antagonists
MX9300433A (es) * 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
US5387684A (en) * 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
WO1994001409A1 (fr) * 1992-07-02 1994-01-20 Fujisawa Pharmaceutical Co., Ltd. Nouvel intermediaire pour la synthese et la production d'un derive d'aminoacide
EP0656356A1 (fr) * 1992-08-21 1995-06-07 Japan Tobacco Inc. Compose dioxacycloalcane a activite inhibitrice de la renine
ATE163927T1 (de) * 1992-11-09 1998-03-15 Knoll Ag 1,4-benzothiazepine verwendbar als neurologische mittel
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
US5719155A (en) * 1993-11-10 1998-02-17 Japan Tobacco Inc. Chroman derivative and pharmaceutical use thereof
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) * 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
DE69534685T2 (de) * 1994-06-15 2006-09-07 Kirin Beer K.K. Transferase und amylase, verfahren zur herstellung dieser enzyme, ihre verwendung und für die kodierende gene
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
CN1131202C (zh) * 1996-07-08 2003-12-17 麒麟麦酒株式会社 钙受体活性化合物
US5785178A (en) * 1996-11-04 1998-07-28 Minnesota Mining And Manufacturing Co. Packaged photocurable composition
ATE290068T1 (de) * 1996-12-12 2005-03-15 Kirin Brewery Beta 1-4 n-acetylglucosaminyltransferase sowie das für diese kodierende gen
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US20030064406A1 (en) * 1997-10-08 2003-04-03 Noboru Kaneko Process for analyzing annexin-V in urine, and application thereof
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
AU1682699A (en) * 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
NZ507760A (en) * 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
PL343424A1 (en) * 1998-04-10 2001-08-13 Japan Tobacco Inc Amidine compounds
EP1085879A2 (fr) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Agents de liaison multiple, modulant le transporteur de 5-ht
EP1122311A4 (fr) * 1998-07-31 2002-04-17 Kirin Brewery Medicaments permettant de soigner la neuropathie contenant de la galectine-1 ou ses derives comme substance active
EP1147772B1 (fr) * 1998-12-28 2006-01-04 Noboru Kaneko utilisation de derivées 1,4-benzothiazepines pour la preparation d'un medicament dans LE TRAITEMENT DE LA FIBRILLATION atriale
CA2368734C (fr) * 1999-03-30 2005-08-23 Japan Tobacco Inc. Procede pour la production d'anticorps monoclonal
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
ATE359788T1 (de) * 1999-09-30 2007-05-15 Noboru Kaneko Verwendung von diphenylmethylpiperazin-derivaten zur herstellung eines medikaments zur unterdrückung der proliferation von fibroblasten
US6568474B2 (en) * 1999-12-20 2003-05-27 Bj Services, Usa Rigless one-trip perforation and gravel pack system and method
WO2001047510A2 (fr) * 1999-12-29 2001-07-05 Glaxo Group Limited Methodes et compositions liees aux modulateurs de l'annexine et de l'homeostasie cartilagineuse
US6906072B1 (en) * 2000-01-20 2005-06-14 Eisai Co., Ltd. Piperazine compound and pharmaceutical composition containing the compound
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
HUP0300632A3 (en) * 2000-05-03 2006-02-28 Warner Lambert Co Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
AU7804501A (en) * 2000-07-27 2002-02-13 Pharmacia Corp Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
TWI290130B (en) * 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
CA2430013C (fr) * 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
US6673904B2 (en) * 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
EP1365022A4 (fr) * 2001-02-01 2004-04-28 Mochida Pharm Co Ltd Proteine associee a l'adiponectine
JP4817514B2 (ja) * 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
JP4175113B2 (ja) * 2001-03-14 2008-11-05 小野薬品工業株式会社 Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
DK1382604T3 (da) * 2001-04-27 2006-04-18 Kirin Brewery Quinolinderivater med en azolylgruppe og quinazolinderivater
BR0212512A (pt) * 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
JP2003145746A (ja) * 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
AU2002354056A1 (en) * 2001-11-19 2003-06-10 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
AU2002349705A1 (en) * 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
US6852753B2 (en) * 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
JPWO2003090570A1 (ja) * 2002-04-26 2005-08-25 日本たばこ産業株式会社 棒状物品の成形装置
JP4113042B2 (ja) * 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
WO2004093896A1 (fr) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions constituees d'un inhibiteur selectif de la cyclooxygenase-2 et d'un modulateur des canaux ioniques du potassium destinees au traitement de lesions du systeme nerveux central
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005016249A2 (fr) * 2003-07-11 2005-02-24 Pharmacia Corporation Compositions constituees d'un inhibiteur chromene ou acide phenylacetique selectif de la cyclooxygenase-2 et d'un inhibiteur de ace pour traiter les lesions du systeme nerveux central
WO2005013907A2 (fr) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Derives de pyrrolo[1,2-b]pyridazine
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
US20070238740A1 (en) * 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
AU2005237494B2 (en) * 2004-04-22 2010-06-10 Kyowa Hakko Kirin Co., Ltd Transgenic animals and uses thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) * 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
MX2007000480A (es) * 2004-07-15 2007-03-29 Japan Tobacco Inc Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1.
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
CA2541847A1 (fr) 2005-04-28
SG147414A1 (en) 2008-11-28
EP1684735A4 (fr) 2009-01-07
CN1886122A (zh) 2006-12-27
WO2005037195A3 (fr) 2005-12-01
JP2007507536A (ja) 2007-03-29
EA200600740A1 (ru) 2006-10-27
WO2005037195A2 (fr) 2005-04-28
KR20060110290A (ko) 2006-10-24
NO20062063L (no) 2006-07-07
EP1684735A2 (fr) 2006-08-02
CN100502845C (zh) 2009-06-24
EA011357B1 (ru) 2009-02-27
AU2004281672A1 (en) 2005-04-28
ZA200603593B (en) 2010-10-27
US20040229781A1 (en) 2004-11-18
BRPI0415434A (pt) 2006-12-05

Similar Documents

Publication Publication Date Title
MA28146A1 (fr) Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique
WO2004027027A3 (fr) Methode d'inhibition de la neovascularisation choroidienne
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA30440B1 (fr) NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2).
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
WO2006028957A8 (fr) Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA29326B1 (fr) Combinaison de composes organiques
MA31001B1 (fr) Quinazolines destines a l'inhibition de pdk
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
EA200001085A1 (ru) 5-аминоиндено [1, 2-с]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
TN2009000018A1 (fr) Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
MA29408B1 (fr) Derives d'aminoacides
ATE453395T1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
EA200870090A1 (ru) Применение производных сульфамида, включающих гетероцикл, конденсированный с бензольным кольцом, для лечения депрессии
EA200501204A1 (ru) Производные 3-(1-[3-(1,3-бензотиазол-6-ил)пропилкарбамоил]циклоалкил)пропановой кислоты в качестве ингибиторов нейтральной эндопептидазы (nep)
MA27844A1 (fr) Derives pyrroliques substitues
MA31562B1 (fr) Macrocycles et leurs utilisations